OGEN · AMEX
Oragenics (OGEN) Stock Price & Fundamentals
Oragenics (OGEN) closed at $648.26 on Oct 9, 2026, up 0.73% from the previous close of $643.54.
Share price, past year
1Y +0.93%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $648.26 |
| Sep 30, 2026 | $643.07 |
| Aug 31, 2026 | $622.71 |
| Jul 31, 2026 | $585.86 |
| Jun 30, 2026 | $589.83 |
| May 29, 2026 | $586.04 |
| Apr 30, 2026 | $578.85 |
| Mar 31, 2026 | $555.72 |
| Feb 27, 2026 | $596.44 |
| Jan 30, 2026 | $585.22 |
| Dec 31, 2025 | $612.62 |
| Nov 28, 2025 | $646.40 |
| Oct 31, 2025 | $644.59 |
Key statistics
- Market cap
- $2.92B
- P/E (TTM)
- 584.0
- EPS (TTM)
- $1.11
- Revenue (TTM)
- —
- Net income (TTM)
- −$10.08M
- Shares outstanding
- 4.5M
- Dividend yield
- —
- 52-week range
- $543.96 – $653.60
Oragenics's market cap is $2.92B, based on a share price of $648.26 and 4.5M shares outstanding as of Jun 30, 2026.
Financials
Oragenics reported revenue of $37.65K for fiscal 2023, down 71.37% from fiscal 2022.
Oragenics reported a net loss of $9.84M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2023ended Dec 31, 2023 | $37.65K | −71.4% | −$20.66M | −54,858.1% | −$9.18 | — |
| FY2022ended Dec 31, 2022 | $131.52K | +51.2% | −$14.29M | −10,864.0% | −$7.11 | −$15.36M |
| FY2021ended Dec 31, 2021 | $86.99K | — | −$15.71M | −18,062.0% | −$0.14 | −$13.51M |
| FY2017ended Dec 31, 2017 | $0.00 | — | −$6.73M | — | −$1.37 | — |
| FY2016ended Dec 31, 2016 | $0.00 | — | −$7.01M | — | −$1.57 | −$7.10M |
| FY2015ended Dec 31, 2015 | $0.00 | −100.0% | — | — | — | −$5.29M |
| FY2014ended Dec 31, 2014 | $939.93K | −8.9% | — | — | — | — |
| FY2013ended Dec 31, 2013 | $1.03M | −22.5% | — | — | — | — |
| FY2012ended Dec 31, 2012 | $1.33M | −7.8% | — | — | — | −$5.22M |
| FY2011ended Dec 31, 2011 | $1.44M | — | — | — | — | — |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2023ended Dec 31, 2023 | $0.00 | — | — |
| Q3 FY2023ended Sep 30, 2023 | $7.47K | — | — |
| Q2 FY2023ended Jun 30, 2023 | $13.16K | — | — |
| Q1 FY2023ended Mar 31, 2023 | $17.02K | — | — |
| Q4 FY2022ended Dec 31, 2022 | $0.00 | — | — |
| Q3 FY2022ended Sep 30, 2022 | $86.05K | — | — |
| Q2 FY2022ended Jun 30, 2022 | $30.39K | — | — |
| Q1 FY2022ended Mar 31, 2022 | $15.08K | — | — |
Company profile
- Name
- Oragenics Inc.
- Ticker
- OGEN
- Exchange
- AMEX
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 9015 Town Center Parkway, Suite 143, Lakewood Ranch, FL 34202
- Incorporated in
- FL
- Fiscal year ends
- December
- SEC CIK
- 0001174940
Recent SEC filings
- Sep 16, 2026
- Aug 28, 2026
- Aug 13, 2026
- Jul 6, 2026
- May 19, 2026
- May 8, 2026
- May 7, 2026
- Apr 13, 2026
Frequently asked questions
What is Oragenics's stock price?
Oragenics (OGEN) closed at $648.26 on Oct 9, 2026, up 0.73% from the previous close of $643.54.
What is Oragenics's market cap?
Oragenics's market cap is $2.92B, based on a share price of $648.26 and 4.5M shares outstanding as of Jun 30, 2026.
How much revenue does Oragenics make?
Oragenics reported revenue of $37.65K for fiscal 2023, down 71.37% from fiscal 2022.
What is OGEN's P/E ratio?
Oragenics's price-to-earnings ratio is 584.0, based on trailing twelve-month diluted EPS of $1.11.
Does Oragenics pay a dividend?
Oragenics's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Oragenics Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures